208 related articles for article (PubMed ID: 24060145)
1. Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.
Yousaf F; Charytan C
Ren Fail; 2014 Feb; 36(1):131-8. PubMed ID: 24060145
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality?
Vervloet MG; du Buf-Vereijken PW; Potter van Loon BJ; Manamley N; Reichert LJ; Smak Gregoor PJ
Neth J Med; 2013 Sep; 71(7):348-54. PubMed ID: 24038560
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
Drüeke TB
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
[TBL] [Abstract][Full Text] [Related]
7. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.
Lien YH; Silva AL; Whittman D
Nephrol Dial Transplant; 2005 Jun; 20(6):1232-7. PubMed ID: 15840675
[TBL] [Abstract][Full Text] [Related]
8. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Tahara H
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
[TBL] [Abstract][Full Text] [Related]
9. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Nakanishi S; Fukagawa M
Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
[TBL] [Abstract][Full Text] [Related]
12. The role of cinacalcet in treating secondary hyperparathyroidism.
Brommage D; Gallgano C
Nephrol Nurs J; 2005; 32(2):229-31. PubMed ID: 15889812
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet: will it play a role in reducing cardiovascular events?
Karohl C; Raggi P
Future Cardiol; 2012 May; 8(3):357-70. PubMed ID: 22420327
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
Quarles LD
Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
[TBL] [Abstract][Full Text] [Related]
17. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.
Bergua C; Torregrosa JV; Fuster D; Gutierrez-Dalmau A; Oppenheimer F; Campistol JM
Transplantation; 2008 Aug; 86(3):413-7. PubMed ID: 18698244
[TBL] [Abstract][Full Text] [Related]
18. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
[TBL] [Abstract][Full Text] [Related]
19. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.
Evenepoel P; Sprangers B; Lerut E; Bammens B; Claes K; Kuypers D; Meijers B; Vanrenterghem Y
Clin Transplant; 2012; 26(3):393-402. PubMed ID: 22007637
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
